Parnell Pharmaceuticals Holdings Ltd. announced consolidated earnings results for the year ended December 31, 2016. For the period, the company reported revenue of AUD 19,048,651 against AUD 13,169,753 a year ago. Loss before income tax was AUD 21,682,389 against AUD 13,735,419 a year ago. Loss for the year was AUD 21,691,443 against AUD 13,737,532 a year ago. Net loss attributable to common stockholders, basic and diluted was AUD 1.37 against AUD 1.03 a year ago.

For the year 2017, the company expects to see continued strong revenue growth from all three Business Segments, and coupled with cost reductions instituted in the 4th quarter of 2016, the company anticipates Parnell returning to EBITDA profitability during 2017.